Clostridium difficile (C. difficile) is a Gram-positive, spore-forming, anaerobic bacillus, which
is widely distributed in the intestinal tract of humans and animals and in the environment. In …

This article reviews the pathogenesis, epidemiology, diagnosis, and treatment of this
nosocomial and potentially fatal infectious diarrhea, as well as the associated risk factors …

Abstract Scope In 2009, the European Society of Clinical Microbiology and Infectious
Diseases (ESCMID) published the first treatment guidance document for Clostridioides …

Triptolide (TP), a traditional Chinese medicine, has been reported to be effective in the
treatment of autoimmune diseases and exerting antineoplastic activity in several human …

Background: To date, evidence for the efficacy of fecal microbiota transplantation (FMT) in
recurrent Clostridium difficile infection (CDI) has been limited to case series and open-label …

Background & Aims Fecal microbiota transplantation (FMT) is used commonly for treatment
of Clostridioides difficile infections (CDIs), although prospective safety data are limited and …

OBJECTIVES: Patients who are immunocompromised (IC) are at increased risk
ofClostridium difficileinfection (CDI), which has increased to epidemic proportions over the …

Clostridium difficileinfection (CDI) is a leading cause of hospital-associated gastrointestinal
illness and places a high burden on our health-care system. Patients with CDI typically have …

There are few high-quality studies of the costs of Clostridium difficile infection (CDI), and the
majority of studies focus on the costs of CDI in acute-care facilities. Analysis of the best …

The most common cause of antibiotic-associated diarrhea is Clostridium difficile infection
(CDI). Recurrent C. difficile infection (rCDI) often occurs after successful treatment of CDI …